For research use only. Not for therapeutic Use.
Bimagrumab (Anti-ACVR2B Reference Antibody) is a human monoclonal antibody that blocks activin type II receptor (ActRII), with KDs of 1.7 pM and 434 pM for human ActRIIB and ActRIIA, respectively. Bimagrumab can be used for the research of pathological muscle loss and weakness[1][2].
BYM338 (1 pM-1 μM; 24 h) inhibits Myostatin- and Activin A-induced Smad2/3-dependent luciferase responses in HEK293 cells with IC50s of 154 and 343 pM, respectively[2].
BYM338 (4 days) prevents the inhibition of differentiation and fusion induced upon exogenous addition of Myostatin or Activin A[2].
BYM338 (6-20 mg/kg; s.c. once weekly for 4 weeks) promotes an increase in body weight and skeletal muscle hypertrophy of all examined muscles, slow, fast, and mixed of young SCID mice[2].
BYM338 (5-20 mg/kg; s.c. once weekly for 14 d) prevents Glucocorticoid-induced muscle wasting in mice[2].
| Catalog Number | I042237 |
| CAS Number | 1356922-05-8 |
| Purity | ≥95% |
| Reference | [1]. Heymsfield SB, et, al. Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial. JAMA Netw Open. 2021 Jan 4;4(1):e2033457. [2]. Lach-Trifilieff E, et, al. An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy. Mol Cell Biol. 2014 Feb;34(4):606-18. |
